# Penumbra Inc: overview

PEN · NYSE · CIK 1321732 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pen.md) · [Financials](/companies/pen/financials.md) · [Filings](/companies/pen/filings.md) · [Insiders](/companies/pen/insiders.md)

Latest reported revenue: [$410.1m](/filings/0001321732-26-000043.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001321732-26-000043).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [316 d](/filings/0001321732-26-000007.md) | [324](/filings/0001321732-26-000019.md) | [339](/filings/0001321732-26-000037.md) | [355](/filings/0001321732-26-000043.md) | [385 d](/filings/0001321732-26-000007.md) | [375](/filings/0001321732-26-000019.md) | [390](/filings/0001321732-26-000037.md) | [410](/filings/0001321732-26-000043.md) |
| Gross margin | % | [66.8% d](/filings/0001321732-26-000007.md) | [66.6%](/filings/0001321732-26-000019.md) | [66.0%](/filings/0001321732-26-000037.md) | [67.8%](/filings/0001321732-26-000043.md) | [68.0% d](/filings/0001321732-26-000007.md) | [67.6%](/filings/0001321732-26-000019.md) | [67.9%](/filings/0001321732-26-000037.md) | [68.3%](/filings/0001321732-26-000043.md) |
| Operating margin | % | [13.6% d](/filings/0001321732-26-000007.md) | [12.4%](/filings/0001321732-26-000019.md) | [12.0%](/filings/0001321732-26-000037.md) | [13.8%](/filings/0001321732-26-000043.md) | [15.4% d](/filings/0001321732-26-000007.md) | [10.2%](/filings/0001321732-26-000019.md) | [10.5%](/filings/0001321732-26-000037.md) | [12.4%](/filings/0001321732-26-000043.md) |
| Net margin | % | [10.7% d](/filings/0001321732-26-000007.md) | [12.1%](/filings/0001321732-26-000043.md) | [13.3%](/filings/0001321732-26-000043.md) | [12.9%](/filings/0001321732-26-000043.md) | [12.3% d](/filings/0001321732-26-000007.md) | [8.7%](/filings/0001321732-26-000043.md) | [8.9%](/filings/0001321732-26-000043.md) | [10.3%](/filings/0001321732-26-000043.md) |
| Diluted EPS | $ per share | not reported | [1.00](/filings/0001321732-26-000019.md) | [1.15](/filings/0001321732-26-000037.md) | [1.17](/filings/0001321732-26-000043.md) | not reported | [0.82](/filings/0001321732-26-000019.md) | [0.88](/filings/0001321732-26-000037.md) | [1.07](/filings/0001321732-26-000043.md) |
| Free cash flow | $m | [45.7 d](/filings/0001321732-26-000007.md) | [35.5](/filings/0001321732-26-000019.md) | [29.4 d](/filings/0001321732-26-000037.md) | [42.0 d](/filings/0001321732-26-000043.md) | [68.1 d](/filings/0001321732-26-000007.md) | [73.3](/filings/0001321732-26-000019.md) | [32.5 d](/filings/0001321732-26-000037.md) | [26.4 d](/filings/0001321732-26-000043.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [748](/filings/0001321732-24-000025.md) | [847](/filings/0001321732-25-000012.md) | [1,059](/filings/0001321732-26-000007.md) | [1,195](/filings/0001321732-26-000007.md) | [1,404](/filings/0001321732-26-000007.md) |
| Gross margin | % | [63.6%](/filings/0001321732-24-000025.md) | [63.2%](/filings/0001321732-25-000012.md) | [64.5%](/filings/0001321732-26-000007.md) | [63.2%](/filings/0001321732-26-000007.md) | [67.1%](/filings/0001321732-26-000007.md) |
| Operating margin | % | [(1.0%)](/filings/0001321732-24-000025.md) | [0.7%](/filings/0001321732-25-000012.md) | [6.9%](/filings/0001321732-26-000007.md) | [0.8%](/filings/0001321732-26-000007.md) | [13.5%](/filings/0001321732-26-000007.md) |
| Net margin | % | [0.7%](/filings/0001321732-24-000025.md) | [(0.2%)](/filings/0001321732-25-000012.md) | [8.6%](/filings/0001321732-26-000007.md) | [1.2%](/filings/0001321732-26-000007.md) | [12.7%](/filings/0001321732-26-000007.md) |
| Diluted EPS | $ per share | [0.14](/filings/0001321732-24-000025.md) | [(0.05)](/filings/0001321732-25-000012.md) | [2.32](/filings/0001321732-26-000007.md) | [0.36](/filings/0001321732-26-000007.md) | [4.52](/filings/0001321732-26-000007.md) |
| Free cash flow | $m | [(11.7)](/filings/0001321732-24-000025.md) | [(75.0)](/filings/0001321732-25-000012.md) | [82.1](/filings/0001321732-26-000007.md) | [147](/filings/0001321732-26-000007.md) | [175](/filings/0001321732-26-000007.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pen/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.36bn | 4,297,555 |  | Reduced −32,901 |
| [HBK INVESTMENTS L P](/funds/1011443.md) | 2026-06-30 | $580.5m | 1,838,508 |  | Added +204,247 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $539.9m | 1,709,877 |  | Added +15,389 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $526.4m | 1,667,276 |  | Added +12,799 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $392.6m | 1,243,258 |  | Added +57,447 |
| [ExodusPoint Capital Management, LP](/funds/1736225.md) | 2026-06-30 | $344.3m | 1,090,430 |  | Added +625,215 |
| [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $344.2m | 1,090,163 |  | Added +328,067 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $338.6m | 1,071,454 |  | Added +668,835 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $267.5m | 847,104 |  | Added +126,529 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $263.6m | 834,903 |  | Added +434,743 |

## Recent filings

[All 941 filings](/companies/pen/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:45 ET | [10-Q](/filings/0001321732-26-000043.md) | Quarterly report, period 2026-09-30 | 0001321732-26-000043 |
| 2026-10-29 | 16:14 ET | [8-K](/filings/0001321732-26-000042.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001321732-26-000042 |
| 2026-07-30 | 16:44 ET | [10-Q](/filings/0001321732-26-000037.md) | Quarterly report, period 2026-06-30 | 0001321732-26-000037 |
| 2026-07-30 | 16:14 ET | [8-K](/filings/0001321732-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001321732-26-000036 |
| 2026-06-22 | 16:19 ET | [8-K](/filings/0001321732-26-000030.md) | 5.07 Shareholder vote results | 0001321732-26-000030 |
| 2026-05-07 | 09:00 ET | [8-K](/filings/0001321732-26-000024.md) | 5.07 Shareholder vote results | 0001321732-26-000024 |
| 2026-05-06 | 16:45 ET | [10-Q](/filings/0001321732-26-000019.md) | Quarterly report, period 2026-03-31 | 0001321732-26-000019 |
| 2026-05-06 | 16:14 ET | [8-K](/filings/0001321732-26-000018.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001321732-26-000018 |
| 2026-04-29 | 16:18 ET | [DEF 14A](/filings/0001321732-26-000010.md) | Proxy statement, period 2026-06-18 | 0001321732-26-000010 |
| 2026-02-25 | 13:27 ET | [10-K](/filings/0001321732-26-000007.md) | Annual report, period 2025-12-31 | 0001321732-26-000007 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001321732-26-000007.md), filed Feb 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/cfeadf8a-6deb-4e50-b9b9-ab48e7a2b651)

## About the filer

- CIK: 1321732
- Tickers: PEN
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 19:10 ET. No prices; not investment advice.